Immunotherapy‐Related Gastritis in Small Cell Lung Cancer Treatment With Durvalumab—A Case Report

This case represents the first report on the rare occurrence of immune-related gastritis in an ES-SCLC patient who has been on immunotherapy for nearly 2 years. Current literature is limited in the understanding of underlying mechanisms of PD-L1-related irAEs and optimal management strategies for rare toxicities like gastritis in immunotherapy-treated cancer patients. This report aims to address the unmet need for further research on rare toxicities to immunotherapy in unique cases.